Taysha Gene Therapies Files Q2 2024 10-Q
Ticker: TSHA · Form: 10-Q · Filed: Aug 12, 2024 · CIK: 1806310
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
**Taysha Gene Therapies files Q2 10-Q. Details on financials and operations.**
AI Summary
Taysha Gene Therapies, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its business operations. Key financial data and operational highlights are detailed within the filing.
Why It Matters
This filing provides investors with crucial financial and operational information for Taysha Gene Therapies, enabling informed investment decisions regarding the company's gene therapy development progress.
Risk Assessment
Risk Level: medium — As a gene therapy company, Taysha Gene Therapies operates in a high-risk, high-reward sector with significant regulatory and development hurdles.
Key Players & Entities
- Taysha Gene Therapies, Inc. (company) — Filer of the 10-Q
- 2024-06-30 (date) — End of the reporting period
- 2024-08-12 (date) — Filing date of the 10-Q
- Dallas, TX (location) — Company's business and mailing address
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended June 30, 2024.
When was this 10-Q filed with the SEC?
This 10-Q was filed on August 12, 2024.
What is Taysha Gene Therapies, Inc.'s primary business sector?
Taysha Gene Therapies, Inc. is in the BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) sector, SIC code 2836.
Where is Taysha Gene Therapies, Inc. located?
The company's business and mailing address is 3000 Pegasus Park Drive, Suite 1430, Dallas, TX 75247.
What is the SEC file number for Taysha Gene Therapies, Inc.?
The SEC file number for Taysha Gene Therapies, Inc. is 001-39536.
Filing Stats: 4,493 words · 18 min read · ~15 pages · Grade level 17.3 · Accepted 2024-08-12 08:32:18
Key Financial Figures
- $0.00001 — ch registered Common stock, par value $0.00001 per share TSHA The Nasdaq Stock Mar
Filing Documents
- tsha-20240630.htm (10-Q) — 1981KB
- tsha-ex4_1.htm (EX-4.1) — 40KB
- tsha-ex31_1.htm (EX-31.1) — 16KB
- tsha-ex31_2.htm (EX-31.2) — 16KB
- tsha-ex32_1.htm (EX-32.1) — 9KB
- tsha-ex32_2.htm (EX-32.2) — 9KB
- img39572056_0.jpg (GRAPHIC) — 48KB
- img39572056_1.jpg (GRAPHIC) — 114KB
- img39572056_2.jpg (GRAPHIC) — 69KB
- img39572056_3.jpg (GRAPHIC) — 97KB
- img39572056_4.jpg (GRAPHIC) — 81KB
- img39572056_5.jpg (GRAPHIC) — 82KB
- img39572056_6.jpg (GRAPHIC) — 86KB
- img39572056_7.jpg (GRAPHIC) — 68KB
- img39572056_8.jpg (GRAPHIC) — 35KB
- img39572056_9.jpg (GRAPHIC) — 88KB
- img39572056_10.jpg (GRAPHIC) — 86KB
- img39572056_11.jpg (GRAPHIC) — 50KB
- img39572056_12.jpg (GRAPHIC) — 78KB
- img39572056_13.jpg (GRAPHIC) — 80KB
- 0000950170-24-095082.txt ( ) — 11925KB
- tsha-20240630.xsd (EX-101.SCH) — 1650KB
- tsha-20240630_htm.xml (XML) — 1628KB
Notes to Financial Statements
Notes to Financial Statements 7 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 28 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 56 Item 4.
Controls and Procedures
Controls and Procedures 56 PART II. OTHER INFORMATION Item 1.
Legal Proceedings
Legal Proceedings 57 Item 1A.
Risk Factors
Risk Factors 57 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 58 Item 3. Defaults Upon Senior Securities 58 Item 4. Mine Safety Disclosures 58 Item 5. Other Information 58 Item 6. Exhibits 59
—FINANCI AL INFORMATION
PART I—FINANCI AL INFORMATION
Financi al Statements
Item 1. Financi al Statements. Taysha Gene Therapies, Inc. Condensed Consolida ted Balance Sheets (in thousands, except share and per share data) (Unaudited) June 30, 2024 December 31, 2023 ASSETS Current assets: Cash and cash equivalents $ 172,743 $ 143,940 Restricted cash 449 449 Prepaid expenses and other current assets 3,278 3,479 Assets held for sale 2,000 2,000 Total current assets 178,470 149,868 Restricted cash 2,151 2,151 Property, plant and equipment, net 10,513 10,826 Operating lease right-of-use assets 8,971 9,582 Other non-current assets 288 304 Total assets $ 200,393 $ 172,731 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 8,718 $ 6,366 Accrued expenses and other current liabilities 11,875 12,284 Deferred revenue 13,583 18,106 Total current liabilities 34,176 36,756 Term loan, net 37,835 40,508 Operating lease liability, net of current portion 18,134 18,953 Other non-current liabilities 1,380 1,577 Total liabilities 91,525 97,794 Commitments and contingencies - Note 13 Stockholders' equity Preferred stock, $ 0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of June 30, 2024 and December 31, 2023 — — Common stock, $ 0.00001 par value per share; 400,000,000 shares authorized and 201,381,450 and 186,960,193 issued and outstanding as of June 30, 2024 and December 31, 2023, respectively 2 2 Additional paid-in capital 664,457 587,942 Accumulated other comprehensive income 2,405 — Accumulated deficit ( 557,996 ) ( 513,007 ) Total stockholders' equity 108,868 74,937 Total liabilities and stockholders' equity $ 200,393 $ 172,731 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 1 Taysha Gene Therapies, Inc. Condensed Consolidated